Disease · MONDO_0008315
Comparisons in its trials655
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 655
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Abiraterone vs Enzalutamide: deaths from any cause | 2,523 of 2,911 | 2,176 of 2,595 | 5,506 | NCT05520138 | Trial comparisons |
| Abiraterone vs Enzalutamide: deaths from any cause | 1,007 of 1,316 | 1,036 of 1,415 | 2,731 | NCT05968599 | Trial comparisons |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): deaths from any cause | 41 of 879 | 42 of 868 | 1,747 | NCT00869206 | Trial comparisons |
| Arm I (Zoledronic Acid Every 4 Weeks) vs Arm II (Zoledronic Acid Every 12 Weeks): serious adverse events | 96 of 879 | 103 of 868 | 1,747 | NCT00869206 | Trial comparisons |
| Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings | 130 of 770 | 163 of 784 | 1,554 | NCT01193244 | Trial comparisons |
| Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events | 321 of 770 | 380 of 784 | 1,554 | NCT01193244 | Trial comparisons |
| Dasatinib vs Placebo: serious adverse events | 381 of 761 | 317 of 757 | 1,518 | NCT00744497 | Trial comparisons |
| Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: deaths from any cause | 119 of 750 | 100 of 742 | 1,492 | NCT00936390 | Trial comparisons |
| TAS x 8 Weeks vs TAS x 28 Weeks: serious adverse events | 121 of 747 | 109 of 735 | 1,482 | NCT00005044 | Trial comparisons |
| Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: Number of Participants With Acute Adverse Events | 152 of 733 | 504 of 725 | 1,458 | NCT00936390 | Trial comparisons |
| Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: serious adverse events | 20 of 733 | 33 of 725 | 1,458 | NCT00936390 | Trial comparisons |
| Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events | 19 of 732 | 10 of 702 | 1,434 | NCT00002651 | Trial comparisons |
| ZD4054 vs Placebo: serious adverse events | 148 of 703 | 138 of 712 | 1,415 | NCT00626548 | Trial comparisons |
Enzalutamide 160 mg vs Placebo: Number of Participants With Treatment-Emergent Adverse Events Greater Than or Equal to Grade 3, Based on National Cancer Institute (NCI) Common Terminology Criteria (CTC) for AEs (CTCAE), Version 4.0 | 292 of 930 | 109 of 465 | 1,395 | NCT02003924 | Trial comparisons |
| Enzalutamide 160 mg vs Placebo: Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs) | 87 of 930 | 28 of 465 | 1,395 | NCT02003924 | Trial comparisons |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Received Treatment for mCRPC and mCSPC | 668 of 795 | 536 of 558 | 1,353 | NCT05701007 | Trial comparisons |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Symptomatic Skeletal-Related Event (SSRE) | 44 of 795 | 43 of 558 | 1,353 | NCT05701007 | Trial comparisons |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With Orchiectomy | 10 of 795 | 9 of 558 | 1,353 | NCT05701007 | Trial comparisons |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants With de Novo Metastasis | 444 of 795 | 240 of 558 | 1,353 | NCT05701007 | Trial comparisons |
| Participants Diagnosed With mCSPC vs Participants Diagnosed With mCRPC: Number of Participants Who Were on Opioids | 310 of 795 | 332 of 558 | 1,353 | NCT05701007 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008315/comparisons